Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pilaralisib + voxtalisib
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A dual-agent, small-molecule combination of the pan-PI3K inhibitor pilaralisib (SAR245408, XL147) and the dual PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) investigated in oncology to inhibit the PI3K/AKT/mTOR signaling pathway. Sanofi developed both agents in collaboration with Exelixis; they were evaluated individually and in combinations with endocrine therapy such as letrozole in hormone receptor–positive, HER2‑negative breast cancer and other cancers. Development of SAR245408 or SAR245409 in combination with letrozole for HR+ advanced or metastatic breast cancer was terminated before completing phase 2 enrollment. The agents were also studied in an open-label extension to assess long‑term safety when used as monotherapy or in combination regimens.[1][3][6][8][10]
- Other names
- pilaralisib and voxtalisib combination
02
Targets
mTOR (Mammalian target of rapamycin kinase)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)
Beyond the preview
Go deeper on pilaralisib + voxtalisib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pilaralisib + voxtalisib.